

Supporting Information
for DOI: 10.1055/a-1308-3773

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Supporting Information

Synthesis of Spiro Oxazolidinedione Analogues Based on Tandem Multicyclizations of 1,3-Dimethylalloxan and Enaminones in Water

Tina Abbasi^a, Mohammad Bagher Teimouri*^b, Issa Yavari*^c, Rahman Bikas^d

^a *Department of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran*

^b *Department of Chemistry, Kharazmi University, Tehran, Iran*

^c *Department of Chemistry, Tarbiat Modares University, Tehran, Iran*

^d *Department of Chemistry, Imam Khomeini International University, Qazvin, Iran.*

Table of Contents:

List of contents	Page	List of contents	Page
Apparatus	S3	¹ H NMR of 4f	S20
Typical procedure for the synthesis of 4a	S3	¹³ C NMR of 4f	S20
Spectral data for 4a	S3	FT-IR of 4g	S21
Spectral data for 4b	S4	¹ H NMR of 4g	S21
Spectral data for 4c	S4	¹³ C NMR of 4g	S22
Spectral data for 4d	S5	FT-IR of 4h	S22
Spectral data for 4e	S5	¹ H NMR of 4h	S23
Spectral data for 4f	S6	¹³ C NMR of 4h	S23
Spectral data for 4g	S6	FT-IR of 4i	S24
Spectral data for 4h	S7	¹ H NMR of 4i	S24
Spectral data for 4i	S7	¹³ C NMR of 4i	S25
Spectral data for 4j	S7	FT-IR of 4j	S25
Spectral data for 5a	S8	¹ H NMR of 4j	S26
Spectral data for 5b	S8	¹³ C NMR of 4j	S26
Spectral data for 5c	S9	FT-IR of 5a	S27
Spectral data for 5d	S9	¹ H NMR of 5a	S27
Spectral data for 5e	S10	¹³ C NMR of 5a	S28
Spectral data for 5f	S10	FT-IR of 5b	S28
Spectral data for 5g	S11	¹ H NMR of 5b	S29
FT-IR of 4a	S12	¹³ C NMR of 5b	S29
¹ H NMR of 4a	S12	FT-IR of 5c	S30
¹³ C NMR of 4a	S13	¹ H NMR of 5c	S30
FT-IR of 4b	S13	¹³ C NMR of 5c	S31
¹ H NMR of 4b	S14	FT-IR of 5d	S31
¹³ C NMR of 4b	S14	¹ H NMR of 5d	S32
FT-IR of 4c	S15	¹³ C NMR of 5d	S32
¹ H NMR of 4c	S15	FT-IR of 5e	S33
¹³ C NMR of 4c	S16	¹ H NMR of 5e	S33
FT-IR of 4d	S16	¹³ C NMR of 5e	S34
¹ H NMR of 4d	S17	FT-IR of 5f	S34
¹³ C NMR of 4d	S17	¹ H NMR of 5f	S35
FT-IR of 4e	S18	¹³ C NMR of 5f	S35
¹ H NMR of 4e	S18	FT-IR of 5g	S36
¹³ C NMR of 4e	S19	¹ H NMR of 5g	S36
FT-IR of 4f	S19	¹³ C NMR of 5g	S37
Details of single crystal X-ray analysis of 4a			S38

Apparatus: Melting points were measured on a Büchi 535 apparatus and are uncorrected. Elemental analyses were performed using an elemental vario EL *III* instrument. FT-IR Spectra were recorded on a Bruker Equinox-55 spectrometer. ^1H and ^{13}C NMR spectra were recorded on a Bruker DRX-300 Avance spectrometer at 300.13 and 75.47 MHz, respectively, with CDCl_3 as solvent and calibrated using residual undeuterated solvent as an internal reference. Analytical TLC was carried out on precoated plates (Merck silica gel 60, F254) and visualized with UV light. All chemical reagents were obtained from Aldrich, Merck, Fluka or Acros and were used without further purification.

Typical procedure for the synthesis of 4 or 5: A mixture of alkylamine **1** (1 mmol) and activated propyne **2** (1 mmol) in water (5 mL) were stirred at room temperature in a round-bottom flask for 3 h. Then, 1,3-dimethylalloxan (1 mmol) was added to the reaction mixture and the stirring was further continued up to 24 h at room temperature until the completion of the reaction as evidenced by TLC monitoring. After completion of the reaction, water was removed using a rotary evaporator. The residue was purified by column chromatography on silica gel with EtOAc/*n*-hexane (1:5) to afford the pure product **4** or **5** as a colorless solid.

Methyl (2*E*)-(3,7-dimethyl-2,4,6-trioxo-1-oxa-3,7-diazaspiro[4.4]non-8-ylidene)acetate (4a):

Colorless powder (0.196 g, 73%); m.p. 200-202 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.55; IR (KBr) (ν_{max} , cm^{-1}): 3090 (=C-H), 1836, 1745, 1743 and 1699 (C=O), 1638 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 3.13 (3 H, s, NCH_3), 3.16 (3 H, s, NCH_3), 3.73 (3 H, s, OCH_3), 3.55 and 3.90 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.3 Hz, $^4J_{\text{HH}}$ 1.8 Hz, CH_2), 5.43 (1 H, t, $^4J_{\text{HH}}$ 1.8 Hz, =CH); ^{13}C

NMR (CDCl₃, 75.5 MHz): δ_C 169.5, 166.8, 166.5, 153.9, 152.4, 95.4, 82.4, 51.5, 33.5, 28.3, 26.8; Anal. Calcd. for C₁₁H₁₂N₂O₆ (268.23): C 49.26, H 4.51, N 10.44%; Found: C 49.47, H 4.57, N 10.37%.

Ethyl (2E)-(3,7-dimethyl-2,4,6-trioxo-1-oxa-3,7-diazaspiro[4.4]non-8-ylidene)acetate (4b):

Colorless powder (0.195 g, 69%), m.p. 140-142 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.56; IR (KBr) (ν_{\max} , cm⁻¹): 3098 (=C-H), 1828, 1748, 1747 and 1698 (C=O), 1651 (C=C); ¹H NMR (CDCl₃, 300.1 MHz): δ_H 1.29 (3 H, t, ³J_{HH} 7.1 Hz, OCH₂CH₃), 3.13 (3 H, s, NCH₃), 3.16 (3 H, s, NCH₃), 3.55 and 3.90 (2 H, d of AB-system, ²J_{HH} 19.2 Hz, ⁴J_{HH} 1.7 Hz, CH₂), 4.19 (2 H, q, ³J_{HH} 7.1 Hz, OCH₂CH₃), 5.43 (1 H, t, ⁴J_{HH} 1.7 Hz, =CH); ¹³C NMR (CDCl₃, 75.5 MHz): δ_C 169.5, 166.8, 166.1, 153.9, 152.1, 95.9, 82.5, 60.3, 33.5, 28.2, 26.8, 14.3; Anal. Calcd. for C₁₂H₁₄N₂O₆ (282.25): C 51.07, H 5.00, N 9.93%; Found: C 50.78, H 5.04, N 10.02%.

Methyl (2E)-(7-ethyl-3-methyl-2,4,6-trioxo-1-oxa-3,7-diazaspiro[4.4]non-8-ylidene)acetate (4c):

Colorless powder (0.217 g, 77%), m.p. 139-141 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.55; IR (KBr) (ν_{\max} , cm⁻¹): 1835, 1738 and 1708 (C=O), 1629 (C=C), ¹H NMR (CDCl₃, 300.1 MHz): δ_H 1.23 (3 H, t, ³J_{HH} 7.2 Hz, OCH₂CH₃), 3.16 (3 H, s, NCH₃), 3.66 (2 H, ABX₃-system, NCH₂CH₃), 3.73 (3 H, s, OCH₃), 3.53 and 3.90 (2 H, d of AB-system, ²J_{HH} 19.3 Hz, ⁴J_{HH} 1.8 Hz, CH₂), 5.46 (1 H, t, ⁴J_{HH} 1.8 Hz, =CH); ¹³C NMR (CDCl₃, 75.5 MHz): δ_C 169.5, 166.6, 153.9, 151.3, 95.0, 82.4, 51.4, 36.9, 33.7, 26.7, 11.6; Anal. Calcd. for C₁₂H₁₄N₂O₆ (282.25): C 51.07, H 5.00, N 9.93%; Found: C 50.79, H 4.94, N 9.88%.

Ethyl (2E)-(7-ethyl-3-methyl-2,4,6-trioxo-1-oxa-3,7-diazaspiro[4.4]non-8-ylidene)acetate

(4d):

Colorless powder (0.222 g, 75%), m.p. 91-93 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.58; IR (KBr) (ν_{\max} , cm^{-1}): 3107 (=C-H), 1831, 1750, 1705 and 1691 (C=O), 1650 (C=C), ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 1.24 (3 H, t, $^3J_{\text{HH}}$ 7.3 Hz, NCH_2CH_3), 1.29 (3 H, t, $^3J_{\text{HH}}$ 7.3 Hz, OCH_2CH_3), 3.17 (3 H, s, NCH_3), 3.59 and 3.86 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.2 Hz, $^4J_{\text{HH}}$ 1.8 Hz, CH_2), 3.62-3.71 (2 H, ABX₃-system, NCH_2CH_3), 4.18 (2 H, q, $^3J_{\text{HH}}$ 7.3 Hz, OCH_2CH_3), 5.45 (1 H, t, $^4J_{\text{HH}}$ 1.8 Hz, =CH); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 169.5, 166.6, 166.2, 153.9, 151.0, 95.4, 82.5, 60.3, 36.9, 33.6, 26.7, 14.3, 11.6; Anal. Calcd. for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_6$ (296.28): C 52.70, H 5.44, N 9.46%; Found: C 53.02, H 5.40, N 9.55%.

(8E)-3,7-Dimethyl-8-(2-oxopropylidene)-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione (4e):

Colorless powder (0.197 g, 78%), m.p. 133-135 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.65; IR (KBr) (ν_{\max} , cm^{-1}): 3071 (=C-H), 1853, 1735, 1703 and 1675 (C=O), 1598 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 2.26 (3 H, s, $\text{O}=\text{C}-\text{CH}_3$), 3.14 (3 H, s, NCH_3), 3.15 (3 H, s, NCH_3), 3.55 and 3.90 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.5 Hz, $^4J_{\text{HH}}$ 1.3 Hz, CH_2), 5.84 (1 H, t, $^4J_{\text{HH}}$ 1.3 Hz, =CH); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 196.6, 169.5, 167.1, 153.6, 151.7, 102.7, 82.4, 34.3, 31.7, 28.3, 26.8; Anal. Calcd. for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_5$ (252.22): C 52.38, H 4.80, N 11.11%; Found: C 52.51, H 4.68, N 11.02%.

(8E)-7-Ethyl-3-methyl-8-(2-oxopropylidene)-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione

(4f):

Colorless powder (0.184 g, 69%), m.p. 137-139 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.61; IR (KBr) (ν_{\max} , cm^{-1}): 1834, 1747, 1734 and 1677 (C=O), 1591 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 1.27 (3 H, t, $^3J_{\text{HH}}$ 7.2 Hz, NCH_2CH_3), 2.29 (3 H, s, O=C-CH₃), 3.18 (3 H, s, NCH₃), 3.67-3.71 (2 H, ABX₃-system, NCH_2CH_3), 3.57 and 3.92 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.5 Hz, $^4J_{\text{HH}}$ 1.3 Hz, CH₂), 5.89 (1 H, t, $^4J_{\text{HH}}$ 1.3 Hz, =CH); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 196.7, 169.5, 167.1, 153.9, 150.7, 102.3, 82.4, 36.9, 34.5, 31.8, 26.7, 11.7; Anal. Calcd. for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_5$ (266.25): C 54.13, H 5.30, N 10.52%; Found: C 53.85, H 5.25, N 10.54%.

(8E)-3-Methyl-8-(2-oxopropylidene)-7-propyl-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione

(4g):

Colorless powder (0.179 g, 64%), m.p. 138-140 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.60; IR (KBr) (ν_{\max} , cm^{-1}): 3061 (=C-H), 1832, 1754, 1739 and 1678 (C=O), 1592 (C=C); ^1H NMR ($\text{DMSO-}d_6$, 300.1 MHz): δ_{H} 0.82 (3 H, t, $^3J_{\text{HH}}$ 7.3 Hz, $\text{NCH}_2\text{CH}_2\text{CH}_3$), 1.55 (2 H, m, $\text{NCH}_2\text{CH}_2\text{CH}_3$), 2.19 (3 H, s, O=C-CH₃), 2.95 (3 H, s, NCH₃), 3.57 (2 H, m, $\text{NCH}_2\text{CH}_2\text{CH}_3$), 3.42 and 3.82 (2 H, AB-system, $^2J_{\text{HH}}$ 19.5 Hz, CH₂), 6.17 (1 H, s, =CH); ^{13}C NMR ($\text{DMSO-}d_6$, 75.5 MHz): δ_{C} 196.8, 170.1, 168.0, 154.6, 151.0, 102.9, 82.7, 42.5, 34.2, 31.5, 26.4, 19.4, 10.8; Anal. Calcd. for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_5$ (280.28): C 55.71, H 5.75, N 10.00%; Found: C 55.56, H 5.68, N 9.94%.

(8E)-7-isobutyl-3-methyl-8-(2-oxopropylidene)-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione (4h):

Colorless powder (0.177 g, 60%), m.p. 177-180 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.60; IR (KBr) (ν_{\max} , cm^{-1}): 1829, 1754, 1737 and 1680 (C=O), 1603 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 0.93 and 0.96 (6 H, 2 d, $^3J_{\text{HH}}$ 6.8 Hz, $\text{CH}(\text{CH}_3)_2$), 2.06-2.16 (1 H, m, $\text{CH}(\text{CH}_3)_2$), 2.26 (3 H, s, O=C-CH₃), 3.16 (3 H, s, NCH₃), 3.35-3.54 (2 H, m, NHCH₂), 3.55 and 3.92 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.5 Hz, $^4J_{\text{HH}}$ 1.6 Hz, CH₂), 5.84 (1 H, s, =CH); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 196.6, 169.6, 167.7, 154.0, 151.4, 102.7, 82.4, 49.0, 34.3, 31.8, 26.7, 26.1, 20.0, 19.8; Anal. Calcd. for C₁₄H₁₈N₂O₅ (294.31): C 57.14, H 6.16, N 9.52%; Found: C 56.98, H 6.13, N 9.45%.

(8E)-7-Allyl-3-methyl-8-(2-oxopropylidene)-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione (4i):

Colorless powder (0.181 g, 65%), m.p. 140-143 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.65; IR (KBr) (ν_{\max} , cm^{-1}): 1834, 1753, 1737, 1678 and 1660 (C=O), 1859 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 2.24 (3 H, s, O=C-CH₃), 3.16 (3 H, s, NCH₃), 3.56 and 3.93 (2 H, d of AB-system, $^2J_{\text{HH}}$ 19.5 Hz, $^4J_{\text{HH}}$ 1.5 Hz, CH₂), 4.22-4.27 (2 H, m, NHCH₂), 5.24 and 5.29 (2 H, 2 d, $^3J_{\text{HH}(\text{trans})}$ 17.2 Hz, $^3J_{\text{HH}(\text{cis})}$ 10.4 Hz, =CH₂), 5.67-5.80 (1 H, m, =CH), 5.83 (1 H, s, =CH); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 196.7, 169.6, 167.9, 153.8, 150.4, 128.4, 118.6, 103.3, 82.4, 43.9, 34.4, 31.8, 26.8; Anal. Calcd. for C₁₃H₁₄N₂O₅ (278.26): C 56.11, H 5.07, N 10.07%; Found: C 55.79, H 4.99, N 10.18%.

(8E)-3-Methyl-8-(2-oxopropylidene)-7-prop-2-yn-1-yl-1-oxa-3,7-diazaspiro[4.4]nonane-2,4,6-trione (4j):

Colorless powder (0.196 g, 71%), m.p. 134-137 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.67; IR (KBr) (ν_{\max} , cm^{-1}): 3315 ($\equiv\text{C-H}$), 1837, 1748 and 1684 (C=O), 1597 (C=C); $^1\text{H NMR}$ (CDCl_3 , 300.1 MHz): δ_{H} 2.28 (3 H, s, O=C-CH₃), 2.35 (1 H, t, $^4J_{\text{HH}}$ 2.5 Hz, $\equiv\text{CH}$), 3.15 (3 H, s, NCH₃), 3.58 and 3.92 (2 H, AB-system, $^2J_{\text{HH}}$ 19.6 Hz, CH₂), 4.32 and 4.45 (2 H, d of AB-system, $^2J_{\text{HH}}$ 17.6 Hz, $^4J_{\text{HH}}$ 2.5 Hz, $\equiv\text{C-CH}_2$), 6.04 (1 H, s, =CH); $^{13}\text{C NMR}$ (CDCl_3 , 75.5 MHz): δ_{C} 196.6, 169.2, 166.4, 153.7, 149.1, 103.9, 82.2, 74.3, 74.1, 34.3, 31.8, 31.1, 26.8; Anal. Calcd. for C₁₃H₁₂N₂O₅ (276.25): C 56.52, H 4.38, N 10.14%; Found: C 56.35, H 4.40, N 10.17%.

Methyl 3-methyl-2,4,6-trioxo-8-piperidin-1-yl-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5a):

Colorless powder (0.200 g, 62%); m.p. 193-195 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.50; IR (KBr) (ν_{\max} , cm^{-1}): 1816, 1727, 1701 and 1667 (C=O), 1592 (C=C); $^1\text{H NMR}$ (CDCl_3 , 300.1 MHz): δ_{H} 1.79 (6 H, m, CH₂CH₂CH₂), 3.01 and 3.24 (2 H, AB-system, $^2J_{\text{HH}}$ 16.6 Hz, CH₂), 3.12 (3 H, s, NCH₃), 3.54 (4 H, m, CH₂NCH₂), 3.82 (3 H, s, OCH₃); $^{13}\text{C NMR}$ (CDCl_3 , 75.5 MHz): δ_{C} 185.7, 170.9, 170.3, 164.3, 154.4, 103.7, 85.4, 53.2, 51.5, 50.7, 35.7, 26.0, 25.9, 25.2, 23.0; Anal. Calcd. for C₁₅H₁₈N₂O₆ (322.32): C 55.90, H 5.63, N 8.69%; Found: C 56.17, H 5.60, N 8.76%.

Ethyl 3-methyl-2,4,6-trioxo-8-piperidin-1-yl-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5b):

Colorless powder (0.222 g, 66%); m.p. 115-117 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.53; IR (KBr) (ν_{\max} , cm^{-1}): 1820, 1742, 1711 and 1678 (C=O), 1568 (C=C); $^1\text{H NMR}$ (CDCl_3 , 300.1 MHz): δ_{H} 1.32 (3 H, t, $^3J_{\text{HH}}$ 7.1 Hz, OCH_2CH_3), 1.76 (6 H, m, $\text{CH}_2\text{CH}_2\text{CH}_2$), 3.00 and 3.22 (2 H, AB-system, $^2J_{\text{HH}}$ 16.6 Hz, CH_2), 3.10 (3 H, s, NCH_3), 3.53 (4 H, m, CH_2NCH_2), 4.26 (2 H, q, $^3J_{\text{HH}}$ 7.1 Hz, OCH_2CH_3); $^{13}\text{C NMR}$ (CDCl_3 , 75.5 MHz): δ_{C} 185.7, 170.7, 170.4, 164.2, 154.7, 103.2, 85.8, 60.9, 53.4, 51.0, 35.9, 26.4, 26.2, 25.6, 23.4, 14.2; Anal. Calcd. for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_6$ (336.34): C 57.14, H 5.99, N 8.33%; Found: C 56.88, H 6.08, N 8.28%.

Methyl 3-methyl-8-morpholin-4-yl-2,4,6-trioxo-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5c):

Colorless powder (0.204 g, 63%); m.p. 193-195 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.60; IR (KBr) (ν_{\max} , cm^{-1}): 1820, 1745, 1723 and 1662 (C=O), 1576 (C=C); $^1\text{H NMR}$ (CDCl_3 , 300.1 MHz): δ_{H} 3.04 and 3.24 (2 H, AB-system, $^2J_{\text{HH}}$ 16.7 Hz, CH_2), 3.12 (3 H, s, NCH_3), 3.62-3.72 (4 H, m, CH_2NCH_2), 3.81 (3 H, s, OCH_3), 3.88 (4 H, m, CH_2OCH_2); $^{13}\text{C NMR}$ (CDCl_3 , 75.5 MHz): δ_{C} 185.8, 171.4, 170.4, 163.8, 154.5, 103.1, 85.4, 66.4, 66.3, 52.4, 52.1, 50.0, 35.8, 26.5; Anal. Calcd. for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_7$ (324.29): C 51.85, H 4.97, N 8.64%; Found: C 51.67, H 5.05, N 8.53%.

Ethyl 3-methyl-8-morpholin-4-yl-2,4,6-trioxo-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5d):

Colorless powder (0.230 g, 68%); m.p. 177-180 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.62; IR (KBr) (ν_{\max} , cm^{-1}): 1820, 1724, 1722 and 1663 (C=O), 1599 (C=C); $^1\text{H NMR}$ (CDCl_3 , 300.1 MHz):

δ_{H} 1.32 (3 H, t, $^3J_{\text{HH}}$ 7.1 Hz, OCH_2CH_3), 3.03 and 3.22 (2 H, AB-system, $^2J_{\text{HH}}$ 16.7 Hz, CH_2), 3.10 (3 H, s, NCH_3), 3.61-3.70 (4 H, m, CH_2NCH_2), 3.86 (4 H, s, CH_2OCH_2), 4.25 (2 H, q, $^3J_{\text{HH}}$ 7.1 Hz, OCH_2CH_3); ^{13}C NMR (CDCl_3 , 75.5 MHz): δ_{C} 186.1, 171.1, 170.5, 163.9, 154.6, 103.7, 85.5, 66.3, 61.1, 52.2, 49.9, 35.7, 26.5, 14.2; Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_7$ (338.32): C 53.25, H 5.36, N 8.28%; Found: C 52.97, H 5.32, N 8.25%.

Methyl 3-methyl-2,4,6-trioxo-8-thiomorpholin-4-yl-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5e):

Colorless powder (0.242 g, 71%); m.p. 197-199 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.65; IR (KBr) (ν_{max} , cm^{-1}): 1814, 1751, 1704 and 1682 (C=O), 1578 (C=C); ^1H NMR (DMSO- d_6 , 300.1 MHz): δ_{H} 2.77 (4 H, m, CH_2SCH_2), 2.87 (2 H, m, CH_2), 2.95 (3 H, s, NCH_3), 3.55-3.95 (4 H, m, CH_2NCH_2), 3.67 (3 H, s, OCH_3); ^{13}C NMR (DMSO- d_6 , 75.5 MHz): δ_{C} 186.1, 171.3, 170.8, 164.5, 155.0, 102.6, 85.8, 54.1, 52.2, 51.7, 35.5, 26.9, 26.2, 26.1; Anal. Calcd. for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_6\text{S}$ (340.35): C 49.41, H 4.74, N 8.23%; Found: C 49.53, H 4.69, N 8.31%.

Ethyl 3-methyl-2,4,6-trioxo-8-thiomorpholin-4-yl-1-oxa-3-azaspiro[4.4]non-7-ene-7-carboxylate (5f):


Colorless powder (0.241 g, 68%); m.p. 195-197 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.65; IR (KBr) (ν_{max} , cm^{-1}): 1820, 1743, 1725 and 1667 (C=O), 1591 (C=C); ^1H NMR (CDCl_3 , 300.1 MHz): δ_{H} 1.31 (3 H, t, $^3J_{\text{HH}}$ 7.1 Hz, OCH_2CH_3), 2.82-2.96 (4 H, m, CH_2SCH_2), 3.02 and 3.20 (2 H, AB-system, $^2J_{\text{HH}}$ 16.7 Hz, CH_2), 3.09 (3 H, s, NCH_3), 3.79-3.86 (4 H, m, CH_2NCH_2), 4.25 (2 H, q, $^3J_{\text{HH}}$

7.1 Hz, OCH_2CH_3); ^{13}C NMR ($CDCl_3$, 75.5 MHz): δ_c 186.1, 170.7, 170.5, 164.2, 154.6, 104.2, 85.4, 61.2, 55.0, 52.6, 35.8, 27.8 and 27.1, 26.5, 14.2; Anal. Calcd. for $C_{15}H_{18}N_2O_6S$ (354.38): C 50.84, H 5.12, N 7.91%; Found: C 51.05, H 5.18, N 8.01%.


Ethyl (2E)-(7-isopropyl-3-methyl-2,4,6-trioxo-1-oxa-3,7-diazaspiro[4.4]non-8-ylidene)acetate (5g):

Colorless powder (0.208 g, 67%), m.p. 176-179 °C (dec.); R_f (25% EtOAc/*n*-hexane) 0.60; IR (KBr) (ν_{max} , cm^{-1}): 3248 (N-H), 1821, 1755, 1705 and 1660 (C=O), 1605 (C=C); 1H NMR ($CDCl_3$, 300.1 MHz): δ_H 1.32-1.39 (9 H, m, 3 CH_3 overlapping), 3.12 (3 H, s, NCH_3), 3.02 and 3.33 (2 H, AB-system, $^2J_{HH}$ 17.9 Hz, CH_2), 3.79-3.82 (1 H, m, CH), 4.28 (2 H, q, $^3J_{HH}$ 7.1 Hz, OCH_2CH_3), 9.36 (1 H, br. d, $^3J_{HH}$ 7.7 Hz, NH); ^{13}C NMR ($CDCl_3$, 75.5 MHz): δ_c 184.1, 175.5, 170.9, 166.0, 154.7, 99.0, 85.4, 60.5, 47.5, 32.3, 26.5, 23.4, 23.3, 14.2; Anal. Calcd. for $C_{14}H_{18}N_2O_6$ (310.31): C 54.19, H 5.85, N 9.03%; Found: C 53.96, H 5.83, N 9.07%.


FT-IR of (4a):




¹H NMR (300 MHz, CDCl₃) of (4a):




^{13}C NMR (75 MHz, CDCl_3) of (4a):




FT-IR of (4b):




^1H NMR (300 MHz, CDCl_3) of (4b):




^{13}C NMR (75 MHz, CDCl_3) of (4b):




FT-IR of (4c):




¹H NMR (300 MHz, CDCl₃) of (4c):




^{13}C NMR (75 MHz, CDCl_3) of (4c):




FT-IR of (4d):




¹H NMR (300 MHz, CDCl₃) of (4d):




¹³C NMR (75 MHz, CDCl₃) of (4d):




FT-IR of (4e):




¹H NMR (300 MHz, CDCl₃) of (4e):




^{13}C NMR (75 MHz, CDCl_3) of (4e):




FT-IR of (4f):




^1H NMR (300 MHz, CDCl_3) of (4f):




^{13}C NMR (75 MHz, CDCl_3) of (4f):




FT-IR of (4g):




¹H NMR (300 MHz, DMSO-d₆) of (4g):




^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) of (4g):




FT-IR of (4h):




¹H NMR (300 MHz, CDCl₃) of (4h):




¹³C NMR (75 MHz, CDCl₃) of (4h):




FT-IR of (4i):




¹H NMR (300 MHz, CDCl₃) of (4i):




¹³C NMR (75 MHz, CDCl₃) of (4i):




FT-IR of (4j):




¹H NMR (300 MHz, CDCl₃) of (4j):




¹³C NMR (75 MHz, CDCl₃) of (4j):




FT-IR of (5a):




¹H NMR (300 MHz, CDCl₃) of (5a):




^{13}C NMR (75 MHz, CDCl_3) of (5a):




FT-IR of (5b):




^1H NMR (300 MHz, CDCl_3) of (5b):




^{13}C NMR (75 MHz, CDCl_3) of (5b):




FT-IR of (5c):




¹H NMR (300 MHz, CDCl₃) of (5c):




¹³C NMR (75 MHz, CDCl₃) of (5c):




FT-IR of (5d):




^1H NMR (300 MHz, CDCl_3) of (5d):




^{13}C NMR (75 MHz, CDCl_3) of (5d):




FT-IR of (5e):




¹H NMR (300 MHz, DMSO-*d*₆) of (5e):




^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) of (5e):




FT-IR of (5f):




¹H NMR (300 MHz, CDCl₃) of (5f):




¹³C NMR (75 MHz, CDCl₃) of (5f):




FT-IR of (5g):



¹H NMR (300 MHz, CDCl₃) of (5g):



¹³C NMR (75 MHz, CDCl₃) of (5g):



Details of single crystal X-ray analysis of 4a:

Suitable single crystals of compound **4a** were obtained by dissolving the compound in methanol and slow solvent evaporating method during three days at room temperature. The data collection was performed on a STOE IPDS-2T diffractometer with graphite monochromated Mo-K α radiation ($\lambda = 0.71073 \text{ \AA}$) at 298 K. A high quality colorless crystal of **4a** was selected and mounted on a glass fiber as a data collector. Orientation matrices and cell constants for collecting data were attained by least-squares refinement of the diffraction data from 3158 unique reflections. Data were obtained in the range of $\theta = 2.4\text{--}29.4^\circ$ in a series of ω scans in 1° oscillations and integrated using Stoe X-AREA [i] software. A numerical absorption correction was used with X-RED [ii] and X-SHAPE [iii] software. The data were refined for Lorentz and Polarizing effects. Solving the structure was done by direct methods and subsequent difference Fourier maps, and finally, refinement on F^2 was carried out by a full-matrix least-squares procedure using anisotropic displacement parameters [iv]. X-STEP32 crystallographic software [v] was applied for the refinements. A summary of the crystal data and refinement details for **4a** are given in Table S1. Crystallographic data (excluding structural factors) for structural analysis have been deposited with the Cambridge Crystallographic Data Centre, no. 2034055 for **4a**.

Table S1. Crystallographic data of **4a**

Compound	4a
Net formula	<u>C₁₁H₁₂N₂O₆</u>
$M_r/\text{g mol}^{-1}$	<u>268.23</u>
Crystal size/mm	<u>0.5</u> \times <u>0.4</u> \times <u>0.3</u>
Crystal shape/color	Plate, Colorless
T/K	298
Radiation	<u>Mo Kα</u> radiation, $\lambda = \text{0.71073 \AA}$
Diffractometer	STOE IPDS 2T diffractometer
Crystal system	<u>Monoclinic</u>
Space group	<u>P2₁/n</u>

$a/\text{\AA}$	10.204(2)
$b/\text{\AA}$	8.3564(17)
$c/\text{\AA}$	13.753(3)
$\beta/^\circ$	93.39(3)
$V/\text{\AA}^3$	1170.7(4)
Z	4
Calc. density/ g cm^{-3}	1.522
μ/mm^{-1}	0.13
Refls. Measured	<u>12773</u>
R_{int}	0.125
h, k, l	-13→13, -9→11, -18→18
Θ range	<u>2.4–29.4</u>
Observed refls.	3158
Refls in refinement	2196
Parameters/Restraints	175/0
$F(000)$	560
$R[F^2 > 2\sigma(F^2)]$	<u>0.062</u>
$wR(F^2)$	<u>0.177</u>
S	1.10
Shift/error _{max}	<0.001
Max/Min electron density/ e \AA^{-3}	0.31/-0.27

[ⁱ] Stoe & Cie, X–AREA: Program for the Acquisition and Analysis of Data, Version 1. 30; Stoe & Cie GmbH: Darmstadt, Germany, 2005.

[ⁱⁱ] Stoe & Cie, X–AREA: Program for the Acquisition and Analysis of Data, Version 1. 30; Stoe & Cie GmbH: Darmstadt, Germany, 2005.

[ⁱⁱⁱ] Stoe & Cie, X–SHAPE: Program for Crystal Optimization for Numerical Absorption Correction, Version 2.05; Stoe & Cie GmbH: Darmstadt, Germany, 2004.

[^v] G.M. Sheldrick, SHELX97, University of Göttingen, Germany, Program for Crystal Structure Refinement, 1997.

[^v] Stoe & Cie, X-STEP32: Crystallographic Package, Version 1.07b; Stoe & Cie, GmbH.; Darmstadt, Germany, 2000.